Is NCT06189963 recruiting in Santa Ana, CA?

Yes, NCT06189963 is currently recruiting participants at its Santa Ana, CA location. This alzheimer's disease clinical trial is actively enrolling qualified participants.

How do I join the alzheimer's disease clinical trial in Santa Ana?

To join this clinical trial in Santa Ana, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Santa Ana clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Alzheimer's Disease Clinical Trial in Santa Ana, CA

About This Alzheimer's Disease Study in Santa Ana

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers

Sponsor: NKGen Biotech, Inc.

Who Can Participate

Inclusion Criteria

The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the participant).

Participants must have a reliable study partner/caregiver (per investigator judgement for instance a family member, partner etc., guardian (must be always the same person)) who is in close contact with the patient, available on call and who is able to contribute to the assessment of the ratings of the functional endpoints at specific study visits. This person will be able to communicate in the language in which the participant is being assessed and should also serve as a backup contact for the study site. The study partner/caregiver must sign a separate informed consent form which describes their contributions during the study.

Patients with diagnosis of Alzheimer's dementia according to the recommendations from the 2011 National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Age 40 to 85 years old.

Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient or their legally authorized representative and documented by the study investigator.

Female participants of childbearing potential must have a negative urine pregnancy test at Screening and Visit 1 before first administration of the study drug. Females of childbearing potential are defined as those who are not surgically sterile or who are not post-menopausal (i.e.: no menses for at least 1 year). Male and female participants of reproductive potential must also agree to abstinence or use acceptable form(s) of effective contraception during the study and for 30 days after the final dose of the study drug. Acceptable methods of contraception include the following:

Condoms, sponges, foams, gels, diaphragms, or intrauterine device (IUD).

Hormonal birth control for 30 days prior to administration of the study drug.

A vasectomized sexual partner.

Positive evidence for a diagnosis of AD via amyloid positron emission tomography (Amyloid PET) of the brain within the past six months.

CDR-SB score of ≥ 9.5 and \<16.0.

Exclusion Criteria

Substantial concomitant cerebrovascular disease defined as Fazekas Grade 3.

History of a stroke/intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment in the opinion of the investigator.

Any substance use disorder that has not been in remission for at least 12 months

Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.

Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without oedema), tachycardia, arrhythmias, uncontrolled hypertension.

History of cerebrovascular accident or transient ischemic attack (TIA), or unexplainable loss of consciousness within the last year.

Significant pulmonary disease predisposing to hypoxia.

Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinically significant heart disease classified as NYHA III or IV.

Significant liver disease (for example cirrhosis, active hepatitis B and C, primary or metastatic liver neoplasm).

Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined during screening.

Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease).

Immunological disorder such as per investigator judgement clinically significant allergies, Lupus erythematodes, or scleroderma.

Uncontrolled/Unstable hematological disease (regardless of cause) such as refractory anemia or refractory myelosuppression.

Neurological disease (such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multi-infarct dementia, stroke, congenital mental deficiency, multiple sclerosis) and psychiatric disorders (such as schizophrenia, or intellectual disability), or any other disorders impacting cognitive function.

Unstable/uncontrolled major depression or anxiety within the last 12 months.

History of seizures in the past three years.

Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or manifest hyperthyroidism, in the opinion of the investigator.

Severe renal impairment defined as a GFR \< 30 mL/min/1.73 m2 in the screening lab report

Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any other infection or active systemic disease.

Currently being treated with anticoagulants (except aspirin at or below a prophylactic dose).

Participants who are taking medications for AD, like memantine or acetylcholinesterase inhibitors (AChEI) that exceeds the normal recommended dose range or have not achieved a stable dose for the 30 days prior to enrollment.

Any contraindication for performing a brain MRI and/or Amyloid PET scan.

Any participant whose safety the investigator considers to be at risk from this trial's intervention.

Participants with any medically unstable/uncontrolled conditions.

Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).

Any suicidal ideation of type 4 or 5 in the C-SSRS in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Santa Ana?

Yes, this clinical trial (NCT06189963) has an active research site in Santa Ana, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Alzheimer's Disease Treatment Options in Santa Ana, CA

If you're searching for alzheimer's disease treatment options in Santa Ana, CA, this clinical trial (NCT06189963) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Santa Ana research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced alzheimer's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alzheimer's disease clinical trials near you to find additional studies recruiting in your area.

Alzheimer's Disease Clinical Trial in Santa Ana, CA

Expert Care in Santa Ana

IRB Approved

No-Cost Care

Apply for This Santa Ana Location

Why Participate?

Simple Process